Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.
|Articles|April 1, 1998
Supplements and Featured Publications
- Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach
- Volume 4
- Issue 4 Suppl
Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?
Advertisement
Articles in this issue
over 28 years ago
Participating Facultyover 28 years ago
Coronary Heart Disease in the United Statesover 28 years ago
Mechanisms of Acute Coronary Eventsover 28 years ago
Primary Preventionover 28 years ago
Pravastatin Event Reduction Analysisover 28 years ago
Secondary Preventionover 28 years ago
Methods and Mindsets in Pharmacoeconomicsover 28 years ago
Issues and Controversies in Pharmacoeconomicsover 28 years ago
Pharmacoeconomics Perspectives: Payers, Providers, and PatientsAdvertisement
Related to this article
The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.
Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap enrollees relative to non–dually eligible traditional Medicare beneficiaries increased from 2013-2024.
Among the therapeutic alternatives used in Medicare’s drug price negotiations, many were generics or biosimilars, and most differed in mechanistic class from the negotiated drug.
In an insured population with advanced lung cancer, clinical trial participants had lower or similar total health care costs compared with nonparticipants.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Medicaid Cuts and Caregiving in Congress: Andy Kim
3
Health Equity & Access Weekly Roundup: November 6, 2026
4
GLP-1 RAs Improve MASLD, MASH Markers, but Long-Term Benefits Unclear
5